Login / Signup

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).

Amar GajjarGiles W RobinsonKyle S SmithTong LinThomas E MerchantMurali ChintagumpalaAnita MahajanJack SuEric BouffetUte BartelsTal SchechterTimothy Eg HassallThomas RobertsonWayne NichollsSridharan GururanganKristin M SchroederMichael SullivanGreg WheelerJordan R HansfordStewart J KellieGeoffrey McCowageRichard CohnMichael J FisherMatthew J KrasinClinton F StewartAlberto BroniscerIvo BuchhalterRuth G TatevossianBrent A OrrGeoffrey A NealePaul KlimoFrederick BoopAshok SrinivasanStefan M PfisterRichard J GilbertsonArzu Onar-ThomasDavid W EllisonPaul A Northcott
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
These results establish a new risk stratification for future medulloblastoma trials.
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • phase ii
  • double blind
  • placebo controlled
  • young adults
  • current status
  • study protocol
  • randomized controlled trial
  • metabolic syndrome
  • skeletal muscle
  • insulin resistance
  • weight loss